4978 ReproCELL
- 130
- -3-2.26%
ReproCELL News
ReproCELL FY Loss Y31.00M Vs Loss Y305.00M
ReproCELL Inc. (4978.TO) Japan Year Ended March 31 GROUP 2024 2023 Revenue Y2.43 bln Y2.95 bln Operating Profit (Y409.00 mln) (Y35
ReproCELL: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
ReproCELL: Notice regarding differences between full-year individual results for the fiscal year ending March 31, 2024 and results for the previous fiscal year
Taiseiken, Obayashi Corporation, Toray, Shiono Yoshi (13th) (1417-5070)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/13 (Mon) ＜1417＞Miraite One ＜1435＞Robohome＜146A＞Colombia ＜1515＞Nippon Steel Mining ＜1518＞Mitsui Matsushima HD ＜1663＞K&O Energy＜167A＞Ryosan Ryoyo ＜1736＞Autech ＜174
Steady, supported by observations of lower US interest rates
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to develop steadily. In the US stock market yesterday 7th, the Dow Average continued to rise slightly for 5 days to 38,884.26 dollars, which was 31.99 dollars higher (+ 0.08%). While expectations for interest rate cuts continued, a decline in long-term interest rates and expectations for corporate settlement supported stock prices. Meanwhile, since President Kashkari of the Minneapolis Fed showed an attitude of not ruling out interest rate hikes, it stalled towards the end of the game. The Nasdaq Composite Index turned down. Buying is excellent in today's emerging markets
Medlec, Note, etc. [Emerging Markets Press Release]
＜3645＞Medical Net Shareholder Benefit System＜4586＞Medlec 28th Stock Acquisition Rights (with exercise price amendment clause) number of shares issued from the 7th, 875,000 shares ＜4582＞ Symbio Pharma downward revisions, operating loss forecast for the current fiscal year △ 3.702 billion yen ← △ 2,837 billion yen ＜4978＞Reprocel downward revision, previous fiscal year operating loss forecast △ 409 million yen ←△ 110 million yen ＜5243＞net subsidiary established and new business started < 7372 > below décolletage HD
Nintendo's 24/3 operating profit increased 4.9% to 528.9 billion yen, 25/3 forecast decreased 24.4% to 400 billion yen
The financial results for the fiscal year ending 2024/3 announced by Nintendo ＜7974＞ were sales of 1.671,865 billion yen, up 4.4% from the previous fiscal year, and operating profit of 528.941 billion yen, up 4.9% from the same period. As for the financial results for the fiscal year ending 2025/3, we plan that sales will decrease 19.3% from the previous fiscal year to 1.35 trillion yen, and operating profit will decrease 24.4% to 400 billion yen. Sales related to the main engine “Nintendo Switch,” which has reached its 8th year of sale, will slow down. It falls below consensus (about 490 billion yen). [Positive Assessment] <61
Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 5/7)
[Good news] ---- ---- ■Maruha Nichiro [Tokyo Stock Exchange P] Current account profit increased by 3%, dividends for the first fiscal year increased by 15 yen, and dividends increased by 15 yen for the current fiscal year. ■Takamatsu Construction Group [Tokyo Stock Exchange P] revised its previous fiscal year accounts upward by 9%. ■Yamato [Tokyo Stock Exchange S]'s current financial results increased 42% and dividends increased by 8 yen. ■Interspace [Tokyo Stock Exchange S] revised its current account for the first half of the year 57%, and the full year also increased. ■Prima Ham
ReproCELL Cuts FY Net to Y31.00M Loss
GROUP New Forecast Prior For Year To Mar 2024 Forecast Revenue Y2.43 bln Y3.05 bln Operating Profit (Y409.00 mln)
ReproCELL: Notice regarding the recording of non-operating income, extraordinary losses, and revisions to the full-year consolidated earnings forecast for the fiscal year ending March 31, 2024
Hatena, Minkabu the Infonoid, etc.
＜175A＞Will SMART Co., Ltd. Zenrin Co., Ltd. Stock Ownership Ratio -% → 44.67% Reporting Obligation Date 2024/04/16 ＜2586＞Frutta Fruta Evo Fund Co., Ltd. Stock Ownership Ratio 40.49% → 40.02% Reporting Obligation Occurrence Date 2024/04/12 ＜3930＞Hatena Co., Ltd. SBI Securities Stock Ownership Ratio 5.09% → 1.80% Report
Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 4/9)
<1439>[Good Material] ――――――――――■Yasue Corporation [Tokyo Stock Exchange S] March order volume increased 10.7% from the same month last year, surpassing the previous year's results for the first time in 2 months. ■Tabio <2668>[Tokyo Stock Exchange S]'s current financial results for the current fiscal year will increase 11%. ■Can Do <2698>[Tokyo Stock Exchange S] Current fiscal year earnings will increase 69%. ■Pal Group Holdings <2726>[Tokyo Stock Exchange P]'s current financial results increased 8% to the highest profit for the 3rd consecutive term. <2923>■Sato Foods [Tokyo Stock Exchange
Is push buying dominant due to steady growth and expectations of a drop in US interest rates
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to develop steadily. In the US stock market yesterday 3rd, the Dow Average continued to fall slightly for 3 days to 39127.14 dollars, which depreciated by 43.10 dollars (-0.11%). ADP employment statistics exceeded expectations, and the view that interest rate cuts were even farther away weighed on stock prices. Meanwhile, in addition to the unexpected decline in the March ISM non-manufacturing business climate index, Chairman Powell of the Federal Reserve (Fed) continues to suggest the possibility of interest rate cuts by the end of the year
LaQuoria Drug Discovery, Reprocel, etc.
＜3195＞Genepa launches a new business (Unique Stores Platform business) ＜4579＞LaQuolia Pharmaceutical signed an agreement with Velovia Pharma, LLC (US) on the development of pet pharmaceuticals ＜4978＞Reprocel research and development business “Research and development to begin corporate clinical trials of cell therapy using cell transplantation of human iPS cell-derived glial progenitor cells (iRP) for amyotrophic lateral sclerosis (ALS)” ANED Public Recruitment Project “Regenerative Medicine
Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 4/3)
Meiho Facility Works has been selected as a “DX certified operator” by the Ministry of Economy, Trade and Industry.
ReproCELL Sees FY Net Y148.00M
ReproCELL Inc. also released the following forecasts: GROUP Year Ending Mar 2024 Revenue Y3.05 bln Operating Profit (Y110.00 mln) Pretax Pro
ReproCELL 9-Mos Net Y48.00M Vs Loss Y39.00M
ReproCELL Inc. (4978.TO) Japan Nine Months Ended December 31 GROUP 2023 2022 Revenue Y1.78 bln Y2.22 bln Operating Profit (Y28
ReproCELL 1H Net Y60.00M Vs Net Y68.00M
ReproCELL Inc. (4978.TO) Japan 1st Half Ended September 30 GROUP 2023 2022 Revenue Y1.15 bln Y1.58 bln Operating Profit (Y241.00 mln)
ReproCELL 1Q Net Y72.00M Vs Net Y42.00M
ReproCELL Inc. (4978.TO) Japan 1st Quarter Ended June 30 GROUP 2023 2022 Revenue Y556.00 mln Y666.00 mln Operating Profit (Y124.00 mln)
Analysis
Price Target
No Data
